Zhiming Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhiming Zhang has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
Zhongyang Song
Department of Oncology, Affiliated Hospital of Gansu University of Traditional Chinese Medicine
9 shared publicationsQian Xu
Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, China
7 shared publicationsLumei Zhang
School of Clinical Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China
6 shared publications- Yongqi Liu
Provincial-Level Key Laboratory for Molecular Medicine of Major Diseases and The Prevention and Treatment with Traditional Chinese Medicine Research in Gansu Colleges and Universities, Gansu University of Chinese Medicine, Lanzhou, China
5 shared publications Bing Zhao
Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, China
4 shared publicationsJingnan Yan
Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, China
4 shared publications
Latest Publications
- 14 July 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 372, 122187
Short-chain fatty acid metabolism in acute lung injury and intervention strategies from traditional Chinese medicine
- 14 July 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 372, 122187
Short-chain fatty acid metabolism in acute lung injury and intervention strategies from traditional Chinese medicine
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1851275
Identification and multi-layered validation of seven diagnostic biomarkers for dilated cardiomyopathy via integrative machine learning, single-cell transcriptomics, and Mendelian randomization
Background: Dilated cardiomyopathy (DCM) is the most common non-ischemic cardiomyopathy and a major cause of heart failure, but disease-specific molecular biomarkers remain limited. This study aimed to identify and prioritize tissue-level, disease-responsive candidate biomarkers for DCM using an integrative multi-omics bioinformatics framework. Methods: Bulk myocardial transcriptomic data from GSE57338 were used as the discovery cohort, and GSE26887, GSE42955, and GSE79962 served as external microarray validation cohorts. GSE116250 was used for independent RNA-seq validation. Differentially expressed genes were intersected with WGCNA hub genes to define candidate genes. Four machine-learning algorithms, including LASSO, random forest, SVM-RFE, and XGBoost, were applied to identify core diagnostic candidates. Tissue-level model performance was evaluated by ROC analysis, calibration assessment, nomogram visualization, and decision curve analysis. Orthogonal validation was performed using GTEx, HPA, and snRNA-seq data. Immune infiltration, bidirectional Mendelian randomization, and CellOracle-based GRN analysis with a co-expression-based functional importance score were used as hypothesis-generating analyses. The workflow explicitly separated diagnostic performance, localization evidence, and exploratory mechanistic context in myocardial tissue. Results: Integration of 309 DEGs and 2,093 WGCNA hub genes yielded 270 candidates. Seven candidates—HMGN2, AQP3, SERPINA3, FREM1, HMOX2, CSDC2, and TUBA3E—were selected by at least three algorithms. In the discovery cohort, the RF model achieved an AUC of 0.985 and the logistic model achieved a C-statistic of 0.993; however, these estimates were interpreted as potentially optimistic upper bounds because feature selection was not nested within cross-validation. External validation showed uneven robustness: SERPINA3, HMOX2, FREM1, and HMGN2 were consistently supported across microarray and RNA-seq cohorts, whereas AQP3, CSDC2, and TUBA3E were exploratory. GTEx, HPA, and snRNA-seq supported cardiac expression and cell-type localization, including cardiomyocyte enrichment of CSDC2/HMOX2 and fibroblast enrichment of FREM1. MR and GRN analyses suggested disease-responsive rather than disease-driving biology, including possible heart failure-associated AQP3 downregulation and a putative PPARGC1A–CSDC2/HMOX2 regulatory context. Conclusion: This study identifies seven prioritized, predominantly disease-responsive tissue-level molecular candidates for DCM. These findings provide candidates and testable hypotheses for future translational research, rather than disease-driving therapeutic targets or a directly applicable clinical test.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1851275
Open AccessIdentification and multi-layered validation of seven diagnostic biomarkers for dilated cardiomyopathy via integrative machine learning, single-cell transcriptomics, and Mendelian randomization
Background: Dilated cardiomyopathy (DCM) is the most common non-ischemic cardiomyopathy and a major cause of heart failure, but disease-specific molecular biomarkers remain limited. This study aimed to identify and prioritize tissue-level, disease-responsive candidate biomarkers for DCM using an integrative multi-omics bioinformatics framework. Methods: Bulk myocardial transcriptomic data from GSE57338 were used as the discovery cohort, and GSE26887, GSE42955, and GSE79962 served as external microarray validation cohorts. GSE116250 was used for independent RNA-seq validation. Differentially expressed genes were intersected with WGCNA hub genes to define candidate genes. Four machine-learning algorithms, including LASSO, random forest, SVM-RFE, and XGBoost, were applied to identify core diagnostic candidates. Tissue-level model performance was evaluated by ROC analysis, calibration assessment, nomogram visualization, and decision curve analysis. Orthogonal validation was performed using GTEx, HPA, and snRNA-seq data. Immune infiltration, bidirectional Mendelian randomization, and CellOracle-based GRN analysis with a co-expression-based functional importance score were used as hypothesis-generating analyses. The workflow explicitly separated diagnostic performance, localization evidence, and exploratory mechanistic context in myocardial tissue. Results: Integration of 309 DEGs and 2,093 WGCNA hub genes yielded 270 candidates. Seven candidates—HMGN2, AQP3, SERPINA3, FREM1, HMOX2, CSDC2, and TUBA3E—were selected by at least three algorithms. In the discovery cohort, the RF model achieved an AUC of 0.985 and the logistic model achieved a C-statistic of 0.993; however, these estimates were interpreted as potentially optimistic upper bounds because feature selection was not nested within cross-validation. External validation showed uneven robustness: SERPINA3, HMOX2, FREM1, and HMGN2 were consistently supported across microarray and RNA-seq cohorts, whereas AQP3, CSDC2, and TUBA3E were exploratory. GTEx, HPA, and snRNA-seq supported cardiac expression and cell-type localization, including cardiomyocyte enrichment of CSDC2/HMOX2 and fibroblast enrichment of FREM1. MR and GRN analyses suggested disease-responsive rather than disease-driving biology, including possible heart failure-associated AQP3 downregulation and a putative PPARGC1A–CSDC2/HMOX2 regulatory context. Conclusion: This study identifies seven prioritized, predominantly disease-responsive tissue-level molecular candidates for DCM. These findings provide candidates and testable hypotheses for future translational research, rather than disease-driving therapeutic targets or a directly applicable clinical test.
- Open Access
- 16 May 2026
- Published by Elsevier in Phytomedicine
- Vol. 157, 158302
Qingfei Tongluo Formula attenuates COPD-associated ferroptosis by restoring arachidonic acid metabolic balance via dual inhibition of prostaglandin-endoperoxide synthase 2 and soluble epoxide hydrolase 2
- 16 May 2026
- Published by Elsevier in Phytomedicine
- Vol. 157, 158302
Open AccessQingfei Tongluo Formula attenuates COPD-associated ferroptosis by restoring arachidonic acid metabolic balance via dual inhibition of prostaglandin-endoperoxide synthase 2 and soluble epoxide hydrolase 2
- 20 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 367, 121719
Corrigendum to ‘Research progress on the regulation of interstitial cell of Cajal autophagy and apoptosis crosstalk by traditional Chinese medicine in gastrointestinal motility disorders’[J. Ethnopharmacol. 2025, 351, 120128]
- 20 April 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 367, 121719
Corrigendum to ‘Research progress on the regulation of interstitial cell of Cajal autophagy and apoptosis crosstalk by traditional Chinese medicine in gastrointestinal motility disorders’[J. Ethnopharmacol. 2025, 351, 120128]
- 14 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158075
Therapeutic potential of Qihuang Biwen Formula and its bioactive compounds for the treatment of ulcerative colitis in Drosophila and mice
- 14 March 2026
- Published by Elsevier in Phytomedicine
- Vol. 155, 158075
Therapeutic potential of Qihuang Biwen Formula and its bioactive compounds for the treatment of ulcerative colitis in Drosophila and mice
- 1 October 2025
- Vol. 45 (5) , 1087-1097
Therapeutic potential of Traditional Chinese Medicine Yisui Shengxue pills to inhibit hypoxia-inducible factor-1alpha and general control nonderepressible 2 to regulate the post-chemotherapy immune response: integrating network pharmacology and experimental validation.
To investigate the efficacy and mechanism of Traditional Chinese Medicine Yishui Shengxue pills (, YSSX) in mouse models of immunosuppression induced by three chemotherapy drugs. We determined an optimal intervention dose of YSSX to investigate efficacy. Changes in immune cell subpopulations were detected by flow cytometry, while immunofluorescence, immunohistochemistry, and other molecular biology methods, were used to verify pathway targets. We used PX-478, an inhibitor of hypoxia-inducible factor-1α (HIF-1α), to validate the mechanism of action. Analysis showed that YSSX enhanced the immunity of mouse models of immunosuppression. At the cellular level, YSSX reduced the numbers of myeloid-derived suppressor cells (MDSCs) and enhanced CD8+ T cell infiltration. At the molecular level, YSSX reduced the expression levels of hypoxia-inducible factor-1α (HIF-1α), inducible nitric oxide synthase (iNOS), general control nonderepressible 2 (GCN2), and eukaryotic initiation factor 2α (eIF2α) in mouse MDSCs, thereby reducing the transcription of HIF-1α, GCN2, and eIF2α mRNA. Collectively, these changes led to the increased secretion of interferon-γ and interleukin 12, concomitant with a reduction in tumor necrosis factor-α level. YSSX improved MDSC-mediated immunosuppression in a mouse model after chemotherapy by inhibiting the HIF-1α/iNOS-GCN2/eIF2α signaling axis.
- 1 October 2025
- Vol. 45 (5) , 1087-1097
Therapeutic potential of Traditional Chinese Medicine Yisui Shengxue pills to inhibit hypoxia-inducible factor-1alpha and general control nonderepressible 2 to regulate the post-chemotherapy immune response: integrating network pharmacology and experimental validation.
To investigate the efficacy and mechanism of Traditional Chinese Medicine Yishui Shengxue pills (, YSSX) in mouse models of immunosuppression induced by three chemotherapy drugs. We determined an optimal intervention dose of YSSX to investigate efficacy. Changes in immune cell subpopulations were detected by flow cytometry, while immunofluorescence, immunohistochemistry, and other molecular biology methods, were used to verify pathway targets. We used PX-478, an inhibitor of hypoxia-inducible factor-1α (HIF-1α), to validate the mechanism of action. Analysis showed that YSSX enhanced the immunity of mouse models of immunosuppression. At the cellular level, YSSX reduced the numbers of myeloid-derived suppressor cells (MDSCs) and enhanced CD8+ T cell infiltration. At the molecular level, YSSX reduced the expression levels of hypoxia-inducible factor-1α (HIF-1α), inducible nitric oxide synthase (iNOS), general control nonderepressible 2 (GCN2), and eukaryotic initiation factor 2α (eIF2α) in mouse MDSCs, thereby reducing the transcription of HIF-1α, GCN2, and eIF2α mRNA. Collectively, these changes led to the increased secretion of interferon-γ and interleukin 12, concomitant with a reduction in tumor necrosis factor-α level. YSSX improved MDSC-mediated immunosuppression in a mouse model after chemotherapy by inhibiting the HIF-1α/iNOS-GCN2/eIF2α signaling axis.
- 26 September 2025
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 41 (10) , 1-22
Immunomodulatory effect of Qihuang Biwen decoction and its postbiotic product
Microbial fermentation is a promising strategy to enhance the efficacy and functional properties of herbs. A traditional Chinese medicine formula, known as the Qihuang Biwen decoction (QHBW), has been shown to have immunomodulatory benefits in clinical and experimental studies. Nevertheless, few studies have investigated the effects of microbial-fermented QHBW (FQHBW) on immunity. In this study, we used one-way and Plackett-Burman analyses to establish the preparation process of FQHBW (crucial parameters: ratio of bacterial strains LZU-J-TSL6 and LZU-S-ZCJ was 3:1, inoculum quantity was 3%, temperature was 37℃, time was 37 h). The study found that FQHBW has increased total polysaccharide, total acid, and antioxidant capacities. The increased constituents after fermentation potentially contribute to improving the ability of FQHBW to regulate immunity. Next, its immunostimulatory activity was evaluated in cyclophosphamide (CTX)-treated mice, and the possible mechanism was studied by microbiome-metabolome analysis. As expected, FQHBW effectively ameliorated CTX-induced immunosuppression by improving organ index, lymphocyte proliferation, phagocytic function, cytokine secretion, and antioxidant profile. It protected against CTX-induced intestinal dysbiosis by promoting the abundance of Oscillospira, Allobaculum, and Coprococcus, while moderately increasing Akkermansia and reducing Staphylococcus and Streptococcus. FQHBW primarily influenced amino acid and nucleotide metabolism to benefit immunity. Unlike QHBW, FQHBW uniquely up-regulates dopamine synapses, tryptophan metabolism, and nicotinate and nicotinamide metabolism, promoting host anti-oxidation, immune system remodeling, and disease resistance. This study suggests that microbial fermentation is indeed an effective strategy to alter the properties and function of QHBW. FQHBW has the potential to replace QHBW as a novel immunoenhancer and intestinal microecological regulator. Graphical abstract
- 26 September 2025
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 41 (10) , 1-22
Immunomodulatory effect of Qihuang Biwen decoction and its postbiotic product
Microbial fermentation is a promising strategy to enhance the efficacy and functional properties of herbs. A traditional Chinese medicine formula, known as the Qihuang Biwen decoction (QHBW), has been shown to have immunomodulatory benefits in clinical and experimental studies. Nevertheless, few studies have investigated the effects of microbial-fermented QHBW (FQHBW) on immunity. In this study, we used one-way and Plackett-Burman analyses to establish the preparation process of FQHBW (crucial parameters: ratio of bacterial strains LZU-J-TSL6 and LZU-S-ZCJ was 3:1, inoculum quantity was 3%, temperature was 37℃, time was 37 h). The study found that FQHBW has increased total polysaccharide, total acid, and antioxidant capacities. The increased constituents after fermentation potentially contribute to improving the ability of FQHBW to regulate immunity. Next, its immunostimulatory activity was evaluated in cyclophosphamide (CTX)-treated mice, and the possible mechanism was studied by microbiome-metabolome analysis. As expected, FQHBW effectively ameliorated CTX-induced immunosuppression by improving organ index, lymphocyte proliferation, phagocytic function, cytokine secretion, and antioxidant profile. It protected against CTX-induced intestinal dysbiosis by promoting the abundance of Oscillospira, Allobaculum, and Coprococcus, while moderately increasing Akkermansia and reducing Staphylococcus and Streptococcus. FQHBW primarily influenced amino acid and nucleotide metabolism to benefit immunity. Unlike QHBW, FQHBW uniquely up-regulates dopamine synapses, tryptophan metabolism, and nicotinate and nicotinamide metabolism, promoting host anti-oxidation, immune system remodeling, and disease resistance. This study suggests that microbial fermentation is indeed an effective strategy to alter the properties and function of QHBW. FQHBW has the potential to replace QHBW as a novel immunoenhancer and intestinal microecological regulator. Graphical abstract
- 23 August 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 164, 115390
Targeting lactate metabolism in the tumor microenvironment: Immunomodulation and prospects for antitumor therapy
- 23 August 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 164, 115390
Targeting lactate metabolism in the tumor microenvironment: Immunomodulation and prospects for antitumor therapy
- Open Access
- 16 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e64725
A Machine Learning Approach to Differentiate Cold and Hot Syndrome in Viral Pneumonia Integrating Traditional Chinese Medicine and Modern Medicine: Machine Learning Model Development and Validation
Background: Syndrome differentiation in traditional Chinese medicine (TCM) is an ancient principle that guides disease diagnosis and treatment. Among these, the cold and hot syndromes play a crucial role in identifying the nature of the disease and guiding the treatment of viral pneumonia. However, differentiating between cold and hot syndromes is often considered esoteric. Machine learning offers a promising avenue for clinicians to identify these syndromes more accurately, thereby supporting more informed clinical decision-making in the treatment. Objective: This study aims to construct a diagnostic model for differentiating cold and hot syndromes in viral pneumonia by integrating TCM and modern medical features using machine learning methods. Methods: The application of 8 machine learning algorithms (gradient boosting machine [GBM], logistic regression, random forest, extreme gradient boosting [XGB], light gradient boosting machine [LGB], ridge regression, least absolute shrinkage and selection operator, and support vector machine) generated and validated (both internally and externally) a model for differentiating cold and hot syndromes in viral pneumonia, based on clinical data from 1484 patient samples collected at 2 medical centers between 2021 and 2022. Results: The GBM model, which combines TCM and modern medicine features, outperformed models using only TCM features or only modern medicine features in distinguishing cold and hot syndromes in patients with viral pneumonia. The optimal discrimination model comprised 13 optimal features (temperature, red cell distribution width-SD, creatinine, total bilirubin, globulin, C-reactive protein, unconjugated bilirubin, white blood cell, neutrophil percentage, aspartate transaminase/alanine transaminase, total cholesterol, thrombocytocrit, and age) and the GBM algorithm, achieving an area under the curve (AUC) of 0.7788. Under internal and external testing, the AUCs were 0.7645 and 0.8428, respectively. Moreover, significant differences were observed between the cold and hot syndrome groups in temperature (P=.02), red cell distribution width-SD (P<.001), neutrophil percentage (P=.01), total cholesterol (P=.003), thrombocytocrit (P<.001), and age (P<.001). Conclusions: This pioneering study integrates the theory of TCM cold and hot syndromes with modern laboratory-based tests through machine learning. The developed model offers a novel approach for differentiating cold and hot syndromes in viral pneumonia, enabling practitioners to identify the syndrome quickly and efficiently, thereby supporting more informed clinical decision-making. Additionally, this research provides new insights into the modernization and scientific interpretation of TCM syndrome differentiation.
- 16 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e64725
Open AccessA Machine Learning Approach to Differentiate Cold and Hot Syndrome in Viral Pneumonia Integrating Traditional Chinese Medicine and Modern Medicine: Machine Learning Model Development and Validation
Background: Syndrome differentiation in traditional Chinese medicine (TCM) is an ancient principle that guides disease diagnosis and treatment. Among these, the cold and hot syndromes play a crucial role in identifying the nature of the disease and guiding the treatment of viral pneumonia. However, differentiating between cold and hot syndromes is often considered esoteric. Machine learning offers a promising avenue for clinicians to identify these syndromes more accurately, thereby supporting more informed clinical decision-making in the treatment. Objective: This study aims to construct a diagnostic model for differentiating cold and hot syndromes in viral pneumonia by integrating TCM and modern medical features using machine learning methods. Methods: The application of 8 machine learning algorithms (gradient boosting machine [GBM], logistic regression, random forest, extreme gradient boosting [XGB], light gradient boosting machine [LGB], ridge regression, least absolute shrinkage and selection operator, and support vector machine) generated and validated (both internally and externally) a model for differentiating cold and hot syndromes in viral pneumonia, based on clinical data from 1484 patient samples collected at 2 medical centers between 2021 and 2022. Results: The GBM model, which combines TCM and modern medicine features, outperformed models using only TCM features or only modern medicine features in distinguishing cold and hot syndromes in patients with viral pneumonia. The optimal discrimination model comprised 13 optimal features (temperature, red cell distribution width-SD, creatinine, total bilirubin, globulin, C-reactive protein, unconjugated bilirubin, white blood cell, neutrophil percentage, aspartate transaminase/alanine transaminase, total cholesterol, thrombocytocrit, and age) and the GBM algorithm, achieving an area under the curve (AUC) of 0.7788. Under internal and external testing, the AUCs were 0.7645 and 0.8428, respectively. Moreover, significant differences were observed between the cold and hot syndrome groups in temperature (P=.02), red cell distribution width-SD (P<.001), neutrophil percentage (P=.01), total cholesterol (P=.003), thrombocytocrit (P<.001), and age (P<.001). Conclusions: This pioneering study integrates the theory of TCM cold and hot syndromes with modern laboratory-based tests through machine learning. The developed model offers a novel approach for differentiating cold and hot syndromes in viral pneumonia, enabling practitioners to identify the syndrome quickly and efficiently, thereby supporting more informed clinical decision-making. Additionally, this research provides new insights into the modernization and scientific interpretation of TCM syndrome differentiation.